Table 1. Relationship between AQP9 expression levels and clinical characteristics in HCC patients.

Parameters	Case number (n=50)	AQP9 expression levels		χ2	P
		Low expression(n=28)	High expression(n=22)
Age (Year)				0.141	0.707
<50	19(38.0%)	10(35.7%)	9(40.9%)
≥50	31(62.0%)	18(64.3%)	13(59.1%)
Gender				0.000	0.988
Male	42(84.0%)	23(82.1%)	19(86.4%)
Female	8(16.0%)	5(17.9%)	3(13.6%)
Tumor size				13.487	0.000
<5cm	24(48.0%)	7(25.0%)	17(77.3%)
≥5 cm	26(52.0%)	21(75.0%)	5(22.7%)
Tumor number				10.959	0.001
Single	19(38.0%)	5(17.9%)	14(63.6%)
Multiple	31(62.0%)	23(82.1%)	8(36.4%)
Tumor grade				0.542	0.462
Poor differentiation	14(28.0%)	9(32.1%)	5(22.7%)
Middle or high differentiation	36(72.0%)	19(77.9%)	17(77.3%)
TNM stage				16.213	0.000
I-II	31(62.0%)	10(35.7%)	21(95.5%)
III-IV	19(38.0%)	18(64.3%)	1(4.5%)
Portal vein tumor thrombus				3.328	0.068
Without	41(82.0%)	20(71.4%)	21(95.5%)
With	9(18.0%)	8(28.6%)	1(4.5%)
Lymph node metastasis				12.158	0.000
Without	38(76.0%)	16(57.1%)	22(100.0%)
With	12(24.0%)	12(42.9%)	0(0.0%)
Distant metastasis				4.266	0.039
Without	40(80.0%)	19(67.9%)	21(95.5%)
With	10(20.0%)	9(32.1%)	1(4.5%)
AFP				1.172	0.279
<400μg/L	41(82.0%)	21(75.0%)	20(90.9%)
≥400μg/L	9(18.0%)	7(25.0%)	2(9.1%)
Cirrhosis				1.096	0.295
Without	30(80.0%)	15(53.6%)	15(68.2%)
With	20(80.0%)	13(46.4%)	7(31.8%)